Early and Chronic Dipeptidyl-Peptidase-IV Inhibition and Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After an Acute Coronary Syndrome: A Landmark Analysis of the EXAMINE Trial

Journal of the American Heart Association
Abhinav SharmaFaiez Zannad

Abstract

Antihyperglycemic therapies may increase the risk of cardiovascular events including hospitalization for heart failure. There is a paucity of data evaluating the cardiovascular safety of antihyperglycemic therapies in the high-risk period following an acute coronary syndrome (ACS). The EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial randomized 5380 patients who were 15 to 90 days post ACS to the dipeptidyl dipeptidase-IV (DPP-IV) inhibitor alogliptin versus placebo; mean follow-up was 18 months. Using a landmark analysis, we assessed the (1) burden of cardiovascular events from randomization to 6 months (early period) and from 6 months to the end of follow-up (late period) and (2) the risk of cardiovascular events associated with early (up to 6 months) and chronic (6 months to end of follow-up) DPP-IV inhibition with alogliptin. Patients with early versus late events had similar baseline demographic profiles. Overall, 42.1% of the composite of cardiovascular death/myocardial infarction/stroke and 47.5% of hospitalization for heart failure occurred in the early period. Early DPP-IV inhibition did not increase the risk of early cardiovascular death/myocardial infarction/stroke (hazar...Continue Reading

References

Mar 23, 2012·Circulation·Marco ValgimigliUNKNOWN Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study (PRODIGY) Investigators
Sep 3, 2013·The New England Journal of Medicine·Benjamin M SciricaUNKNOWN SAVOR-TIMI 53 Steering Committee and Investigators
Sep 3, 2013·The New England Journal of Medicine·William B WhiteUNKNOWN EXAMINE Investigators
Apr 16, 2014·The Lancet. Diabetes & Endocrinology·John J V McMurrayMarc A Pfeffer
Oct 16, 2014·European Journal of Heart Failure·Abhinav Sharma, Justin A Ezekowitz
Feb 11, 2015·JACC. Heart Failure·Alessandra Dei CasGregg C Fonarow
Jun 4, 2015·The New England Journal of Medicine·Christopher P CannonUNKNOWN IMPROVE-IT Investigators
Jun 9, 2015·The New England Journal of Medicine·Jennifer B GreenUNKNOWN TECOS Study Group
Sep 18, 2015·The New England Journal of Medicine·Bernard ZinmanUNKNOWN EMPA-REG OUTCOME Investigators
Dec 3, 2015·The New England Journal of Medicine·Marc A PfefferUNKNOWN ELIXA Investigators
Jan 16, 2016·Annual Review of Medicine·William B White, William L Baker
Jan 29, 2016·European Heart Journal·David FitchettUNKNOWN EMPA-REG OUTCOME® trial investigators
Feb 26, 2016·European Heart Journal·Karl Swedberg, Lars Rydén
Mar 27, 2016·The Lancet. Diabetes & Endocrinology·Abhinav SharmaRobert J Mentz
Jul 22, 2016·JAMA Cardiology·Darren K McGuireUNKNOWN Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS) Study Group
Aug 3, 2016·JAMA : the Journal of the American Medical Association·Kenneth B MarguliesUNKNOWN NHLBI Heart Failure Clinical Research Network
Jun 13, 2017·The New England Journal of Medicine·Bruce NealUNKNOWN CANVAS Program Collaborative Group

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT00968708

Software Mentioned

IMPROVE
SAS
CANVAS

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.